Design: Population-based study using linked national data
Population: 17,738 patients with renal cell carcinoma treated surgically in England, 2019 to 2023
Primary outcome: Treatment within 31 days of decision to treat
Effect: High-risk timely treatment 83.7% (2019) to 64.8% (2023)

This population study linked national data on 7,030 patients with high-risk and 10,708 with low-risk renal cell carcinoma treated surgically in England between 2019 and 2023, measuring whether surgery happened within the 31-day standard from the decision to treat.

For a typical high-risk patient, the chance of timely surgery fell from 83.7% in 2019 to 64.8% in 2023; for low-risk patients, from 71.3% to 47.6%. Delays beyond 62 days more than doubled, from 3.9% to 9.4%. High-risk patients were prioritised throughout (73.6% vs 58.2% timely), but the decline affected both groups. Older and more deprived patients waited longer. Once the 31-day standard was breached, the daily chance of surgery fell sharply.

The study measures delay, not outcomes, and the clinical harm of a given delay varies by tumour.

The lesson travels beyond England: a single target can hide a long tail of patients who, once they miss it, drift further. Tracking those past the target matters as much as hitting it.

Track patients who breach a treatment target, not just the proportion who meet it.
Prioritise high-risk renal tumours explicitly on surgical lists.
Watch for longer delays in older and socioeconomically deprived patients.
Consider ring-fenced capacity for cancer surgery when elective lists are under pressure.

Why it matters

A system can prioritise the right patients and still let all of them wait longer.

The statistics, in plain English

An adjusted risk ratio of 1.26 means high-risk patients were about a quarter more likely to be treated on time than low-risk patients. The study describes waiting times; it does not measure whether the delays changed survival.